Epoetin alfa is 165 amino acid glycoprotein manufactured by recombinant DNA technology, which has similar biological effects as endogenous erythropoietin. Erythropoietin stimulates red blood cell production in-situ. It is a hormone produced in the kidney and augments the differentiation of erythroid progenitors in the bone marrow. Indications of epoetin are as below.

**FDA Approved**

- Chronic kidney disease patients who are on dialysis and not on dialysis

- The patient receiving myelosuppressive therapy for cancer

- Anemia due to zidovudine in HIV-infected patient

- Reduction of allogeneic blood transfusion requirement in the patient who undergoes elective, noncardiac, nonvascular surgery

**NON-FDA Approved**

- Blood transfusion refusing patients like Jehovah’s Witnesses

- Anemia during therapy for chronic hepatitis C

- Myelodysplastic syndrome

- Symptomatic management for anemia

- Preterm anemia